Jason V. Coloma, Chief Executive Officer at Maze Therapeutics, Inc. (MAZE), sold 27,858 shares at $26.00 ($725K) on 2026-06-22, disclosed to the SEC on 2026-06-24.
Scheduled sale ($725k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.00 | 2,040 | $53K | 7.3% |
| 2 | $26.00 | 1,953 | $51K | 7.0% |
| 3 | $26.05 | 23,865 | $622K | 85.7% |
| Total | $26.04 avg | 27,858 | $725K | 100% |
| Filing → |
| MAZE | SELL | 2026-08-05 | $922K | — | Filing → |
| MAZE | SELL | 2026-07-02 | $1.0M | — | Filing → |
| MAZE | SELL | 2026-06-03 | $174K | — | Filing → |